Tuesday, 23 April 2024
Trending

[the_ad_group id="2845"]

Investing

Silk Road Medical Strengthens TCAR Portfolio with Launch of ENROUTE Transcarotid Neuroprotection System PLUS By Investing.com

Natural Gas Inventory +95 bcf vs +88 bcf Expected By Investing.com

[the_ad id="21475"]

[ad_1]

SUNNYVALE, Calif., April 02, 2024 (GLOBE NEWSWIRE) — Silk Road Medical, Inc.  (Nasdaq: NASDAQ:), a company focused on reducing the risk of stroke and its devastating impact, today announced the launch of its ENROUTE ® Transcarotid Neuroprotection System PLUS (NPS PLUS), a key component of the TCAR ® portfolio. This next generation device builds upon the prior ENROUTE Transcarotid Neuroprotection System to deliver smoother arterial sheath insertion, greater flow precision, and a simplified prep experience for surgical teams, all while maintaining unparalleled neuroprotection during the TCAR procedure.

With the launch of the NPS PLUS, we’re thrilled to empower our TCAR-trained physicians with a solution that addresses their insights and feedback to further strengthen and streamline the TCAR procedure, shared Chas McKhann, Chief Executive Officer of Silk Road Medical. Our focus on new product innovation reflects our ongoing commitment to leadership in the treatment of carotid disease.

TCAR combines direct carotid artery access with robust blood flow reversal, providing neuroprotection akin to open surgical techniques in a less invasive, more patient-friendly approach to treating carotid artery disease. During TCAR, the surgical team inserts a tube-like sheath into the carotid artery and connects it to the ENROUTE Neuroprotection System, which temporarily reverses blood flow. The system filters potentially dangerous debris from the blood to reduce intraprocedural stroke risk while the team uses a TCAR-specific balloon and stent to open the artery and contain the carotid artery disease. TCAR delivers less than 1% periprocedural stroke rates and a better patient recovery experience than open surgery.

Silk Road Medical’s responsiveness to our feedback has provided us with better procedure predictability and a more streamlined workflow for our entire surgical team,” remarked Brian Peterson, MD, FACS, FSVS of St. Luke’s Heart and Vascular Institute. “With over 500 TCAR procedures performed by our team, we view TCAR as a first-line treatment option for carotid disease and we’re excited about what these improvements mean for patient care.

Click here for more information on the ENROUTE Neuroprotection System PLUS.

About TCAR with the ENROUTE Transcarotid Neuroprotection and Stent System
TCAR (Transcarotid Artery Revascularization) is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to…

Click Here to Read the Full Original Article at All News…

[ad_2]

[the_ad id="21476"]